AZN LSE Week ended 07 Aug 2026

Weekly Investor Report

AstraZeneca PLC · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 11,896 GBP
-5.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -14.6% below the Trend Line and sits at 35.1% of its 52-week range. The latest completed week returned -5.2%, after a -6.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 55/100.

Setup score 43 out of 100
Latest Close 11,896 GBP 7 Aug 2026
1W Return -5.2% latest completed week
4W Return -6.7% short-term follow-through
12W Return -12.7% quarterly tape
Trend Breadth 65.4% 34 of 52 weeks active
Volume Ratio 3.8x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Volume is elevated versus the 13-week average, confirming attention.
  • Next-week expectancy is positive at 60.74% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.2% Latest completed week; four-week move -6.7%. Indicator stack 36/29 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 60.74% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 55/100 18 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.6% below the Trend Line and sits at 35.1% of its 52-week range. The latest completed week returned -5.2%, after a -6.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 3.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3312-week average 0.47

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.33Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -6.7% over four weeks, -12.7% over 12 weeks, and 8.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.2%
4W-6.7%
12W-12.7%
26W-15.6%
52W8.9%
Active trend streak0 weeks
Active weeks in one year34
Trend breadth65.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.08Latest activity-pressure read.
Pressure change-15.6%Four-week change in activity pressure.
Leadership-18.27Latest relative-leadership reading.
RS change-97.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength48/100Blend of value, momentum, and quality. Underlying universe rank 53; rank 1 is best.
Value8/100Relative valuation strength. Underlying universe rank 93; rank 1 is best.
Quality97/100Profitability and accounting quality. Underlying universe rank 4; rank 1 is best.
Momentum82/100Medium-term price momentum. Underlying universe rank 19; rank 1 is best.
Growth91/100Revenue and earnings growth. Underlying universe rank 10; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework56/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
17.8x
Price divided by trailing earnings.
Price / sales
3.1x
Market value relative to trailing revenue.
EV / EBITDA
10.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
81.7%
Gross profit retained from each unit of revenue.
Operating margin
23.7%
Operating profit retained from revenue.
Free-cash-flow margin
12.8%
Free cash flow generated from revenue.
Return on invested capital
14.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.6%
Latest one-year revenue growth.
EPS growth
45.3%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
19.2%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.0%
Cash dividends relative to market value.
Buyback yield
0.3%
Net share repurchases relative to market value.
Shareholder yield
2.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 18 relevant articles.

4 positive · 12 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-24.4%Distance below the 52-week high.
13-week volatility4.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+8.2%Week of 26 Jun.
Worst week-11.2%Week of 10 Jul.
Latest week-5.2%Week of 7 Aug.

Shape of recent returns

Strong gains3
Modest gains8
Flat weeks0
Modest losses11
Sharp losses4
Recent vol4.3%13-week weekly-return volatility.
Base vol4.2%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -2.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

IndustryGB Drug Manufacturers - General
4-week rank2 / 2
Group average-3.4%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD0.0%positive activity pressure
RS0.0%positive relative leadership

Four-week leaders

GSK · LSE-0.1%AZN · LSE-6.7%
08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape44/100

Trend, activity pressure, participation, and risk combine to a 44/100 tape read.

 Indicator analysis22/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 5/12.

Activity pressure 0.33; No reversal markers Next-Week ExpectancyPositive 60.74%

Next-week expectancy is positive with a 60.74% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 40 SVQF56/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 114.5 of 260 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 18 relevant articles.

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202611,896 GBP-5.2%13,923 GBP11,863 GBP-1.08-18.2742.3MOff
31 Jul 202612,549 GBP-0.3%14,001 GBP11,858 GBP-1.10-13.6617.7MOff
24 Jul 202612,586 GBP0.6%14,035 GBP11,847 GBP-1.02-12.4211.9MOff
17 Jul 202612,511 GBP-1.9%14,072 GBP11,837 GBP-0.84-11.8513.0MOff
10 Jul 202612,749 GBP-11.2%14,110 GBP11,826 GBP-0.93-9.2415.9MOff
3 Jul 202614,361 GBP0.3%14,133 GBP11,810 GBP-1.060.56653.3KOff
26 Jun 202614,318 GBP8.2%14,108 GBP11,783 GBP-1.252.153.9MOff
19 Jun 202613,234 GBP-1.7%14,096 GBP11,764 GBP-1.40-3.994.4MOff
12 Jun 202613,462 GBP-2.9%14,116 GBP11,752 GBP-1.35-3.212.1MOff
5 Jun 202613,858 GBP0.4%14,118 GBP11,741 GBP-1.320.691.7MOff
29 May 202613,802 GBP-0.8%14,086 GBP11,727 GBP-1.340.0611.5MOff
22 May 202613,916 GBP2.1%14,042 GBP11,714 GBP-1.420.497.0MOff
15 May 202613,632 GBP2.0%13,995 GBP11,700 GBP-1.401.2510.8MOff
8 May 202613,360 GBP-1.1%13,960 GBP11,690 GBP-1.15-0.9210.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context